P1vital gains acceptance of the first PReDicT Study publication!
P1vital are pleased to announce that we have gained acceptance of our first PReDicT study publication: “The Clinical Effectiveness of Using a Predictive Algorithm to Guide Antidepressant Treatment in Primary Care (PReDicT): an open-label, randomised controlled trial”.
The objective of the PReDicT Project (Predicting Response to Depression Treatment) was to conduct clinical, health economic and commercial research to validate the clinical performance and to complete the pre-commercial development of the P1vital® PReDicT Test, a novel medical device to improve the treatment and management of depression in clinical practice. The project was co-funded by the Horizon 2020 programme of the European Union.
To view the article, please click here